ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Acasti Pharma Inc

Acasti Pharma Inc (ACST)

3.37
0.00
(0.00%)
Cerrado 20 Noviembre 3:00PM
3.37
0.00
( 0.00% )
Pre Mercado: 6:00PM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
3.37
Postura de Compra
3.20
Postura de Venta
3.63
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
1.98 Rango de 52 semanas 3.60
Capitalización de Mercado [m]
Precio Anterior
3.37
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
25,898
Acciones en circulación
10,140,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.66
Beneficio por acción (BPA)
-1.27
turnover
-
Beneficio neto
-12.85M

Acerca de Acasti Pharma Inc

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced effic... Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all which could help to increase treatment compliance and improve patient outcomes. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Jersey City, New Jersey, USA
Fundado
-
Acasti Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACST. The last closing price for Acasti Pharma was US$3.37. Over the last year, Acasti Pharma shares have traded in a share price range of US$ 1.98 to US$ 3.60.

Acasti Pharma currently has 10,140,000 shares in issue. The market capitalisation of Acasti Pharma is US$34.17 million. Acasti Pharma has a price to earnings ratio (PE ratio) of -2.66.

ACST Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1003.373.373.3700CS
4-0.17-4.802259887013.543.583.273403.39431743CS
120.8232.15686274512.553.62.1256258983.05121848CS
260.6624.35424354242.713.62.1256180682.97532343CS
521.2659.71563981042.113.61.98213992.95196128CS
156-5.39-61.52968036538.7610.74121.721946667.22985343CS
260-9.47-73.75389408112.8418.481.02647478893.91456276CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
ESGROEnstar Group Ltd
US$ 28.00
(40.92%)
28
CCECCapital Clean Energy Carriers Corporation
US$ 24.99
(34.72%)
11
WSBFWaterstone Financial Inc
US$ 9.00
(-40.98%)
4
TRSTriMas Corporation
US$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
US$ 11.00
(-40.15%)
212
PYXSPyxis Oncology Inc
US$ 2.43
(-36.39%)
209.56k
XNCRXencor Inc
US$ 15.11
(-36.30%)
2
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
XTKGX3 Holdings Company Ltd
US$ 0.0775
(-13.89%)
10.83M
CRKNCrown Electrokinetics Corporation
US$ 0.9853
(25.41%)
5.59M

ACST Discussion

Ver más
Lime Time Lime Time 3 semanas hace
ACST to GRCE, 10/28/2024
👍️0
glenn1919 glenn1919 2 meses hace
ACST................................https://stockcharts.com/h-sc/ui?s=ACST&p=W&b=5&g=0&id=p86431144783
👍️0
makinezmoney makinezmoney 2 años hace
$ACST: Thats good news.... now 0.67

EF Hutton gave them a $2.50 Target.


Hmmmmmmmmmmmmmmmmm



Looking for an entry here


GO $ACST
👍️0
Eurotradr Eurotradr 2 años hace
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
https://www.acasti.com/en/investors/news-events/press-releases/detail/239/acasti-pharma-announces-preliminary-topline-results-met-all
👍️0
kzivann kzivann 3 años hace
News. Premarket volume.

ACST
👍️0
kzivann kzivann 3 años hace
Bid filled @ 88 new low.

ACST
👍️0
kzivann kzivann 3 años hace
Bid filled @ 88 new low.

ACST
👍️0
Eurotradr Eurotradr 3 años hace
ACST Acasti Pharma Price Target announced at $6.00 by Oppenheimer. 12/21/20
👍️0
georgie18 georgie18 3 años hace
ACST...$1.69...Psar flipped Bullish on the second Highest Green Volume Day in the history of ACST...

Chart... https://schrts.co/VuKYQNpa ...
👍️0
georgie18 georgie18 3 años hace
ACST...$1.64s clearing here...:partying_face:
👍️0
crudeoil24 crudeoil24 3 años hace
SEC 424B5 > We have entered into a sales agreement with B. Riley Securities, Inc., Oppenheimer & Co. Inc., and H.C. Wainwright & Co., LLC (collectively the “Agents” and each an “Agent”), relating to the sale of our common shares, no par value per common share, offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and sell from time to time our common shares having an aggregate offering price of up to US$75,000,000 through or to the Agents, each acting as sales agent or principal.
👍️0
Disquisition Disquisition 3 años hace
DUMPED all my shares at 1.40
👍️0
georgie18 georgie18 3 años hace
ACST...$1.41...in the P/M...plus 27%...:partying_face: https://www.benzinga.com/analyst-ratings/price-target/21/12/24728317/acasti-pharma-shares-spike-higher-after-hours-as-oppenheimer-initiates-coverage-on-s
👍️0
Disquisition Disquisition 3 años hace
LOADED THE BOAT AT 1.04
👍️0
Disquisition Disquisition 3 años hace
LOADED MORE AT 1.10
👍️0
Disquisition Disquisition 3 años hace
LOADED AT 1.16
👍️0
Disquisition Disquisition 3 años hace
Loaded MORE at 1.20

Let’s do this
👍️0
Disquisition Disquisition 3 años hace
LOADED THE BOAT at $1.52.

Let’s do this.
👍️0
Eurotradr Eurotradr 3 años hace
ACST - Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan
Acasti Pharma, Inc.
Wed, October 6, 2021, 8:30 AM

Patents strengthen Acasti’s IP portfolio and provide protection through 2036 and 2037, respectively

LAVAL, Québec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office and the Mexican Patent Office have issued composition of matter patents for GTX-101, a novel bio-adhesive film forming topical spray formulation of bupivacaine for the treatment of Postherpetic Neuralgia (PHN). PHN is a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years. GTX-101 could provide significant benefits over the current standard of care including greater convenience, faster onset of action and longer duration of pain relief. The granted patents are valid until 2036.

In addition, the Japanese Patent Office has granted a composition of matter patent for GTX-102, a novel, easy-to-use oral mucosal spray formulation of betamethasone, intended to improve neurological symptoms of Ataxia-telangiectasia (A-T). A-T is a progressive, neurodegenerative genetic disease that primarily affects children causing severe physical disability, for which no treatment currently exists. The granted patent is valid until 2037.

Jan D’Alvise, Chief Executive Officer of Acasti, stated, “These latest patents are important additions to our intellectual property portfolio, expanding product protection to additional important international markets as we continue to progress these drug candidates through clinical studies. We believe these granted composition of matter patents further support the commercial potential of GTX-101 and GTX-102. Both drug candidates have already received Orphan Drug Designation from the FDA and could address important underserved global markets. The goal of these proprietary formulations is to improve the quality of care and patient outcomes by providing significant efficacy, safety and convenience benefits including ease of use, faster onset of action and extended relief.”

https://finance.yahoo.com/news/acasti-pharma-awarded-composition-matter-123000390.html
👍️0
xLeGenDx xLeGenDx 3 años hace
Loaded $1.98, let’s ??
👍️0
georgie18 georgie18 3 años hace
ACST...$2.22...Bullish Descent Block Reversal Pattern to the Upside formed on this Oversold Pincher Squeeze set up...imo...we shall see...

Adding here on the post split dip...

Chart... https://schrts.co/rWzDkaBw ...
👍️0
Monksdream Monksdream 3 años hace
Hard to catch a falling knife.

The price could easily decline below $2. Maybe not today, but over a period of days.
👍️0
kzivann kzivann 3 años hace
Back in.

ACST
👍️0
Monksdream Monksdream 3 años hace
You ain't kidding. All the shareholders prior to the reverse split are selling to salvage what they can.
👍️0
Disquisition Disquisition 3 años hace
INDEFATIGABLE DUMPING
👍️0
kzivann kzivann 3 años hace
Watch after RS.


ACST
👍️0
georgie18 georgie18 3 años hace
ACST/ACSTX...$30.40...1/8 Reverse Split...https://www.otcmarkets.com/filing/html?id=15192357&guid=iOP9kW-VfXy9sth

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management’s current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D’Alvise as President and Chief Executive Officer, under the oversight of Acasti’s newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and commercial presence in North Brunswick, New Jersey.
👍️0
kzivann kzivann 3 años hace
Very nice premarket..

ACST
👍️0
kzivann kzivann 3 años hace
Got some...

ACST
👍️0
georgie18 georgie18 3 años hace
I am as well...
👍️0
GREGG THE GREEK GREGG THE GREEK 3 años hace
Still holding a nice position here.


ACST
👍️0
georgie18 georgie18 3 años hace
ACST...4668...Forming a strong confirmation candle following the Bullish Doji Star on the close from yesterday...imo...we shall see...:partying_face:
👍️0
GREGG THE GREEK GREGG THE GREEK 3 años hace
Adding some back here.


ACST
👍️0
georgie18 georgie18 3 años hace
ACST...57...in the P/M...on the Gappa...:partying_face:
👍️0
Eurotradr Eurotradr 3 años hace
"As part of the Acasti annual and special meeting, Acasti will be seeking the shareholder approvals necessary to complete the merger, elect directors and for other related matters. The 2021 annual and special meeting of Acasti shareholders will be held virtually on August 26, 2021, at 1:00 p.m. (Eastern Time), unless postponed or adjourned to a later date."
👍️0
Marvy Marvy 3 años hace
When is the merger?
👍️0
Eurotradr Eurotradr 3 años hace
Premarket looking very nice. Let's see if we can crack $1.00 near term.
👍️0
Eurotradr Eurotradr 3 años hace
Form S-4/A - https://newsfilter.io/articles/s-4a-form---amend-registration-of-securities-business-combinations---acasti-pharma-inc-0001444192-fi-13bc4f13124dae71b281efeaa56a65fc
👍️0
GREGG THE GREEK GREGG THE GREEK 3 años hace
ACST
Here we go !!


Nice pop !!!
👍️0
scooter1ar scooter1ar 3 años hace
watch $AMIH to breakout coming there to
👍️0
GREGG THE GREEK GREGG THE GREEK 3 años hace
Definitely looks to be shaping up nicely.
Next week. Couple weeks. Whatever.

It’s all good.
In fact. Life is great.

We are blessed to be in the position we’re in.
Where our biggest worry is how soon we’ll bank lol

Have a great weekend !!!


ACST
👍️0
scooter1ar scooter1ar 3 años hace
Looks like a good week coming next week ,,
👍️0
GREGG THE GREEK GREGG THE GREEK 3 años hace
Going to get that push again and it's going to be a good one.


ACST
👍️0
scooter1ar scooter1ar 3 años hace
Buying time on this one
👍️0
GREGG THE GREEK GREGG THE GREEK 3 años hace
If you're not trading this one around a core, you're missing out on a lot of profits.


Been a great money maker.


ACST
👍️0
Survivor2012 Survivor2012 3 años hace
https://www.streetinsider.com/dr/news.php?id=18634612&gfv=1
👍️0
georgie18 georgie18 3 años hace
ACST...5997...:partying_face:
👍️0
Eurotradr Eurotradr 3 años hace
Let's make some money today. Happy trading!!!
👍️0
georgie18 georgie18 3 años hace
Gap was at 563 to 573...ACST...5779...in the P/M...Gap filled yesterday...:party:
[8:04 AM]
georgie18 — Yesterday at 7:41 AM
ACST...57...in the P/M...Added here in this range...Looking for the .56 dip n rip on the Gap Fill...imo...we shall see...:party:
👍️0
Eurotradr Eurotradr 3 años hace
Gap at .59 no reason we should not hit that today.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock